Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has entered into a services agreement with Nanosoft Polymers to support the development of ONC010, the company's lead nanoparticle-formulated PNKP inhibitor. The collaboration aims to strengthen the manufacturing and formulation foundation of ONC010 as it progresses through IND-enabling development and preparation for future clinical studies.
Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. These efforts are intended to establish scalable polymer production processes, enhance analytical methods and support future GMP manufacturing readiness. The partnership complements ongoing chemistry, manufacturing and controls (CMC) activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics as Onco advances ONC010 toward first-in-human clinical evaluation.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours. ONC010, a nanoparticle-formulated PNKP inhibitor, represents a novel approach to cancer therapy by targeting a key DNA repair enzyme, potentially enhancing the efficacy of radiation and chemotherapy.
This development is significant for the oncology industry as it addresses a critical need for more targeted and effective cancer treatments. By advancing ONC010 toward clinical trials, Onco-Innovations could provide a new therapeutic option for patients with solid tumours, potentially improving outcomes and reducing side effects compared to conventional therapies. The collaboration with Nanosoft underscores the importance of robust manufacturing processes in bringing innovative cancer drugs to market, ensuring that the therapy can be produced at scale with consistent quality.
Investors and stakeholders in the biotech sector will be watching Onco-Innovations' progress closely, as successful IND-enabling studies and clinical trials could position the company as a key player in the nanoparticle-based oncology space. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. For more details on the full press release, visit https://ibn.fm/djEgt.
Onco-Innovations' strategic partnerships and focus on scalable manufacturing highlight the company's commitment to advancing its pipeline. The implications for patients and the broader oncology community are substantial, as ONC010 could represent a meaningful advancement in the fight against cancer. With continued support from partners like Nanosoft, Dalton Pharma Services and Nucro-Technics, Onco-Innovations is well-positioned to move its lead candidate toward the clinic and, ultimately, to patients in need.
